{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:36:33Z","timestamp":1794663393487,"version":"4.9.1"},"reference-count":164,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eururo.2026.04.014","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:10:05Z","timestamp":1784099405000},"page":"270-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142026 Update: Treatment of Relapsing and Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"90","author":[{"given":"Derya","family":"Tilki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Epure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania Linares","family":"Espinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria De","family":"Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Stranne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Cornford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.04.014_b0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.04.013","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: screening, diagnosis, and local treatment with curative intent","author":"Cornford","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research ed)"},{"key":"10.1016\/j.eururo.2026.04.014_b0020","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1177\/02841851231184210","article-title":"Diagnostic performance of 18F-labeled PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"64","author":"Yang","year":"2023","journal-title":"Acta Radiol"},{"key":"10.1016\/j.eururo.2026.04.014_b0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0030","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A Phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0035","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.04.014_b0040","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med: Off Publ, Soc Nucl Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.775387","article-title":"Targeting local recurrence after surgery with MRI imaging for prostate cancer in the setting of salvage radiation therapy","volume":"12","author":"Renard-Penna","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/iju.12960","article-title":"Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy","volume":"23","author":"Song","year":"2016","journal-title":"Int J Urol: Off J Japanese Urol Assoc"},{"key":"10.1016\/j.eururo.2026.04.014_b0055","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2017.11.012","article-title":"Multiparametric magnetic resonance imaging is an independent predictor of salvage radiotherapy outcomes after radical prostatectomy","volume":"73","author":"Sharma","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041246","article-title":"The prognostic value of DCE-MRI findings before salvage radiotherapy after radical prostatectomy","volume":"15","author":"Farneti","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.04.014_b0065","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2214\/AJR.22.28665","article-title":"PI-RR: the prostate imaging for recurrence reporting system for MRI assessment of local prostate cancer recurrence after radiation therapy or radical prostatectomy-a review","volume":"220","author":"Abreu-Gomez","year":"2023","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2026.04.014_b0075","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1007\/s00330-023-09949-7","article-title":"An MRI assessment of prostate cancer local recurrence using the PI-RR system: diagnostic accuracy, inter-observer reliability among readers with variable experience, and correlation with PSA values","volume":"34","author":"Franco","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2026.04.014_b0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bju.14944","article-title":"Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature","volume":"125","author":"Luiting","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.04.014_b0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2018.12.055","article-title":"Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy","volume":"129","author":"Boreta","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.04.014_b0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"(68)Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng\/ml. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.eururo.2026.04.014_b0095","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11307-019-01424-4","article-title":"Whole-body integrated [(68)Ga]PSMA-11-PET\/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET\/CT as the standard of reference","volume":"22","author":"Guberina","year":"2020","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.eururo.2026.04.014_b0100","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.118.225185","article-title":"The contribution of multiparametric pelvic and whole-body MRI to interpretation of (18)F-Fluoromethylcholine or (68)Ga-HBED-CC PSMA-11 PET\/CT in patients with biochemical failure after radical prostatectomy","volume":"60","author":"Metser","year":"2019","journal-title":"J Nucl Med: Off Publ, Soc Nucl Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0105","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.04.014_b0110","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00330-009-1647-4","article-title":"Imaging of prostate cancer local recurrences: why and how?","volume":"20","author":"Rouviere","year":"2010","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2026.04.014_b0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jmri.26581","article-title":"Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy","volume":"50","author":"Dinis Fernandes","year":"2019","journal-title":"J Magnet Reson Imag: JMRI"},{"key":"10.1016\/j.eururo.2026.04.014_b0120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1148\/radiol.13122149","article-title":"Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?","volume":"268","author":"Donati","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2026.04.014_b0125","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1007\/s00330-018-5819-y","article-title":"Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy","volume":"29","author":"Dinis Fernandes","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2026.04.014_b0130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030781","article-title":"Value of targeted biopsies and combined PSMA PET\/CT and mp-MRI imaging in locally recurrent prostate cancer after primary radiotherapy","volume":"14","author":"Rasing","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.04.014_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110535","article-title":"Intra-prostatic recurrences after radiotherapy with focal boost: location and dose mapping in the FLAME trial","volume":"201","author":"Menne Guricova","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0145","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.juro.2009.08.027","article-title":"Radiation therapy after radical prostatectomy: impact on metastasis and survival","volume":"182","author":"Boorjian","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0150","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.ijrobp.2019.06.456","article-title":"A phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 08.03 and ANZUP \u201cRAVES\u201d Trial","volume":"105","author":"Kneebone","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.04.014_b0155","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0160","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0170","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the european association of urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Eng J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2017.06.027","article-title":"A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer","volume":"73","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0190","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(24)00802-X","article-title":"Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management","volume":"403","author":"Pollack","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.04.014_b0195","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0200","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110532","article-title":"Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: an individual patient data analysis of randomized trials from ICECaP database","volume":"201","author":"Pommier","year":"2024","journal-title":"Radioth Oncol: J Eur Soc Therap Radiol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0210","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk stratification of patients with recurrence after primary treatment for prostate cancer: a systematic review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0215","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0220","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0225","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eururo.2025.05.013","article-title":"Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for nonmetastatic prostate cancer: a collaborative systematic review and meta-analysis of aggregate data","volume":"88","author":"Burdett","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0230","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0235","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Eng J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0240","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","author":"Shore","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0245","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMe2309502","article-title":"Biochemical recurrence in prostate cancer \u2014 tilting the scale","volume":"389","author":"Aparicio","year":"2023","journal-title":"N Eng J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0250","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0255","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0260","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.03.019","article-title":"Prostate-specific antigen response as a prognostic factor for overall survival in patients with prostate cancer treated with androgen receptor pathway inhibitors: a systematic review and meta-analysis","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.014_b0275","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0280","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0285","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.07.003","article-title":"Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"84","author":"Rydzewska","year":"2017","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"10.1016\/j.eururo.2026.04.014_b0295","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201cHigh-\u201d and \u201cLow-risk\u201d Metastatic Hormone-sensitive Prostate Cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0305","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0310","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0315","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0320","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0325","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0330","article-title":"Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving apalutamide: secondary analysis of the TITAN trial","author":"Fukuokaya","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0335","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0340","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41392-024-02064-z","article-title":"Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.eururo.2026.04.014_b0345","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0350","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113290","article-title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study","volume":"193","author":"Merseburger","year":"2023","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.eururo.2026.04.014_b0360","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0365","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2021.39.15_suppl.5000","article-title":"A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and\/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): first results of PEACE-1","volume":"39","author":"Fizazi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0370","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0375","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0380","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2999","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0390","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0395","article-title":"Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: a systematic review and network meta-analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eururo.2026.04.014_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2026.04.014_b0405","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.04.014_b0410","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CAD.0000000000001419","article-title":"A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens","volume":"34","author":"Ramos-Esquivel","year":"2023","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.eururo.2026.04.014_b0415","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41391-022-00607-5","article-title":"Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"26","author":"Rajwa","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.04.014_b0420","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/bcp.16176","article-title":"Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: a systematic review and network meta-analysis","volume":"90","author":"Xiao","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2026.04.014_b0425","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2025.01.010","article-title":"Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer","volume":"87","author":"Azad","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0430","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0435","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0440","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0450","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0455","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","article-title":"Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"86","author":"Roy","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0460","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.euo.2024.06.002","article-title":"Current treatment paradigms and clinical outcomes in oligometastatic prostate cancer patients: a targeted literature review","volume":"7","author":"Antonarakis","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0465","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0470","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0475","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0480","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0485","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0490","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0495","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/ijc.35052","article-title":"Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial","volume":"155","author":"See","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2026.04.014_b0500","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0505","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.euo.2018.09.005","article-title":"Novel insights into the management of oligometastatic prostate cancer: a comprehensive review","volume":"2","author":"Battaglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0510","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euo.2020.07.004","article-title":"Targeting oligometastasis with stereotactic ablative radiation therapy or surgery in metastatic hormone-sensitive prostate cancer: a systematic review of prospective clinical trials","volume":"3","author":"Connor","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0515","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euros.2021.02.008","article-title":"Oligorecurrent prostate cancer and stereotactic body radiotherapy: where are we now? a systematic review and meta-analysis of prospective studies","volume":"27","author":"Marvaso","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2026.04.014_b0520","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082271","article-title":"Oncological outcomes of metastasis-directed therapy in oligorecurrent prostate cancer patients following radical prostatectomy","volume":"12","author":"Devos","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.04.014_b0525","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0530","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0535","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.eururo.2026.04.014_b0540","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >\/=24 weeks in Europe","volume":"74","author":"de Bono","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0545","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.23.02182","article-title":"US food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Heiss","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0550","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0555","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of Poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US food and drug administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0560","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0565","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO-24-01283","article-title":"Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial","volume":"43","author":"Petrylak","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0570","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.eururo.2026.04.014_b0575","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0580","unstructured":"U.S. Food and Drug Administration. FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer. 2023."},{"key":"10.1016\/j.eururo.2026.04.014_b0585","unstructured":"U.S. Food & Drug Adminstration. FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer. 2023."},{"key":"10.1016\/j.eururo.2026.04.014_b0590","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.04.014_b0595","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0600","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0605","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0610","unstructured":"European Medicines Agency. Akeega. 2023."},{"key":"10.1016\/j.eururo.2026.04.014_b0615","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0620","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0625","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0630","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0635","unstructured":"U.S. Food and Drug Administration. FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer. 2023."},{"key":"10.1016\/j.eururo.2026.04.014_b0640","article-title":"ODAC rejects label expansion for talazoparib in non-HRRm mCRPC","author":"Sava","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0645","unstructured":"European Medicines Agency. Talzenna - opinion on variation to marketing authorisation. 2023."},{"key":"10.1016\/j.eururo.2026.04.014_b0650","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0655","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2024.11.027","article-title":"Decrease in fracture rate with mandatory bone-protecting agents in the EORTC 1333\/PEACE-3 trial comparing Radium-223 combined with enzalutamide versus enzalutamide alone: a safety analysis","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0660","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0665","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0670","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0675","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0680","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0685","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0690","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0695","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0700","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0705","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0710","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0715","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [(177)Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0720","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2023.41.6_suppl.18","article-title":"Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy","volume":"41","author":"Bryce","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0725","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0730","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1200\/JCO.2022.40.16_suppl.5000","article-title":"177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel\u2014Overall survival after median follow-up of 3 years (ANZUP 1603)","volume":"40","author":"Hofman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0735","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0740","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0745","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","article-title":"Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [(177)Lu]Lu-PSMA-617 in the phase 3 VISION trial","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.04.014_b0750","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00259-024-06825-4","article-title":"Efficacy and safety of rechallenge [(177)Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)","volume":"51","author":"Rosar","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.eururo.2026.04.014_b0755","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2967\/jnumed.121.262017","article-title":"Effects of (225)Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: a meta-analysis","volume":"63","author":"Lee","year":"2022","journal-title":"J Nucl Med: Off Publ, Soc Nucl Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0760","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0765","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0770","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0775","unstructured":"European Medicines Agency. Lynparza (olaparib). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza: EMA; 2014."},{"key":"10.1016\/j.eururo.2026.04.014_b0780","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0785","unstructured":"U.S. Food and Drug Adminstration. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate: U.S. FDA; 2020."},{"key":"10.1016\/j.eururo.2026.04.014_b0790","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0795","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0800","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0805","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.04.014_b0810","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eururo.2026.04.014_b0815","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.04.014_b0820","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.870","article-title":"Final overall survival (OS) analysis of PROfound: olaparib vs physician\u2019s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations","volume":"31","author":"de Bono","year":"2020","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826021160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:25:53Z","timestamp":1788740753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826021160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":164,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0302283826021160"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142026 Update: Treatment of Relapsing and Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}